NOVAVAX INC

Their core work

Novavax is a US biopharmaceutical company whose primary business is developing and manufacturing vaccines against respiratory viruses, with RSV (Respiratory Syncytial Virus) as a longstanding core program. In European H2020 research, they participated as an industry partner in large, multi-country RSV epidemiology consortia — contributing vaccine-developer expertise to studies that quantify the real-world burden of RSV disease, build biobanks, and design surveillance infrastructure across European populations. Their participation is commercially motivated: the epidemiological evidence generated by these projects directly supports regulatory submissions and market access strategies for Novavax RSV vaccines in Europe. They bring the industry perspective that academic-led consortia need to translate research findings into actionable immunisation policy.

What they specialise in

How they've shifted over time

Across both projects the RSV focus is constant, but a meaningful shift is visible: RESCEU (2017) centered on building the evidence base from scratch — retrospective routine data, systematic literature reviews, burden of disease quantification, and cohort studies. PROMISE (2021) carries those same epidemiological tools forward but adds immunisation as an explicit objective, reflecting the maturation of Novavax's own RSV vaccine pipeline toward regulatory approval and European market entry. The trajectory is from "characterizing the disease" to "preparing systems to deploy vaccines against it."

Novavax is moving from generating disease burden evidence to positioning for commercial vaccine deployment in Europe — future collaborations are likely to focus on post-marketing surveillance, health technology assessment data, and immunisation programme design.

How they like to work

Novavax participates exclusively as a consortium member, never as coordinator — a pattern typical of large pharmaceutical companies that join academic-led consortia to access epidemiological data they need for regulatory purposes rather than to lead research programs. Their two projects each involve large, pan-European networks (24 unique partners across 10 countries for just 2 projects), indicating a preference for flagship, high-visibility consortia over small focused collaborations. The fact that both projects carry zero disclosed EC funding confirms they participate under IMI (Innovative Medicines Initiative) co-funding rules, where industry partners contribute in-kind rather than receiving grants.

Despite only two H2020 projects, Novavax has engaged 24 distinct consortium partners across 10 countries — an unusually broad network for such a small project count, reflecting the large, pan-European character of IMI-funded RSV research that spans academic medical centers, public health agencies, and industry across the EU.

What sets them apart

Novavax is the only US-headquartered vaccine manufacturer with a documented double presence in Europe's two flagship RSV research programs (RESCEU and PROMISE), giving them unmatched continuity of insight into European RSV epidemiology from 2017 through 2024. Unlike academic partners who generate data, Novavax holds the commercial vaccine development capability that converts that data into products — making them a bridge partner between research consortia and public health procurement. For consortium builders who need an industry anchor with deep RSV regulatory experience and a real stake in European immunisation outcomes, Novavax is a rare fit.

Highlights from their portfolio

• RESCEU
  One of the largest and longest-running RSV epidemiology studies in Europe (2017–2022), covering retrospective, prospective, and surveillance data across multiple countries under IMI funding — the foundational RSV evidence project on the continent.
• PROMISE
  Direct sequel to RESCEU focused on translating RSV epidemiology into immunisation programme readiness (2021–2024), marking the transition from disease characterization to vaccine deployment infrastructure — coinciding with Novavax's RSV vaccine regulatory timeline.